Separation of anxiety and depressive disorders: Blind alley in psychopharmacology and classification of disease

British Medical Journal

Volumn 327, Issue 7407, 2003, Pages 158-160

  Shorter, Edward ^a   Tyrer, Peter ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPNOTIC SEDATIVE AGENT; MIRTAZAPINE; MOCLOBEMIDE; MODAFINIL; NEUROLEPTIC AGENT; NEW DRUG; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZALEPLON; ZOLPIDEM;

ANXIETY DISORDER; DEPRESSION; DISEASE CLASSIFICATION; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; HUMAN; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SIDE EFFECT; SOCIAL PHOBIA;

EID: 0038713946     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7407.158     Document Type: Review

References (19)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association.
2. Blashfield RK, Fuller AK. Predicting the DSM-V. J Nerv Ment Dis 1996;184:4-7.
3. Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003;160:4-12.
4. Tyrer P. Comorbidity or consanguinity. Br J Psychiatry 1996;168:669-71.
5. Jenkins R, Lewis G, Bebbington P, Brugha T, Farrell M, Gill B, et al. The national psychiatric morbidity surveys of Great Britain - initial findings from the household survey. Psychol Med 1997;27:775-89.
6. Casey P, Dowrick C, Wilkinson G. Adjustment disorders: fault line in the psychiatric glossary. Br J Pychiatry 2001;179:479-81.
7. European Agency for the Evaluation of Medicinal Products. Concept paper on the development of a committee for proprietary medicinal products note to guidance on clinical investigation of medicinal products for the treatment of generalised anxiety disorder. www.cmea.eu.int/pdfs/human/ewp/428402en.pdf (accessed 23 May 2003).
8. Bero LA. The publication of sponsored symposiums in medical journals. N Engl J Med 1992;327:1135-40.
9. Tyrer P. The case for cothymia: mixed anxiety and depression as a single diagnosis. Br J Psychiatry 2001;179:191-3.
10. Shorter E. Looking backwards: a possible new path for drug discovery in psychopharmacology. Nature Rev Drug Discov 2002;1:1003-6.
11. Romach M, Busto U, Somer G, Kaplan HI, Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry 1995;152:1161-7.
12. Mendlewicz J, Lecrubier Y. Antidepressant selection: proceedings from a TCA/SSRI consensus conference. Acta Psychiat Scand Suppl 2000;403:5-8.
13. Hudson JI, Pope HGJ. Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry 1990;147:552-64.
14. Spitzer R. Letter to "Dear Colleague," 8 May 1984. Anxiety meeting folder. J Williams papers, DSM-III-R files, box 3. Washington, DC: American Psychiatric Association Archives, 1994.
15. Bass A. Drug companies enrich Brown professor. Boston Globe 1999 Apr 10: http://www.prozactruth.com/moneytrail.htm (accessed 9 Jun 2003).
16. Cauchon D. FDA advisers tied to industry. USA Today 2000 Sep 25:1.A http://pqasb.pqarchiver.com/USAToday (accessed 9 Jun 2003).
17. Denber HCB. Notes from another time and place. In: Ban T, Healty D, Shorter E. The rise of psychopharmacology and the story of CINP. Budapest: Animula. 1988:371.
18. Schoenbauer R. Uni-Psychiater unter "Ghostwriting" Verdacht. Der Standard 2002 May 11-12.
19. Healy D. Some continuities and discontinuities in the pharmacotherapy of nervous conditions before and after chlorpromazine and imipramine. Hist Psychiatry 2000;11:393-412.